Navigation Links
Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
Date:7/2/2008

- Top-line Data Expected in August -

EXTON, Pa., July 2 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today the completion of the pivotal efficacy portion of its Phase III clinical studies (IT-R-005/006) investigating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles. The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The Company anticipates that top-line efficacy and safety data analyses from the studies will be reported in August 2008.

"The completion of the pivotal efficacy portion of our Phase III clinical studies is a major milestone for Isolagen," said Declan Daly, Chief Executive Officer of Isolagen. "I commend the Isolagen team and our investigators for their efforts and look forward to announcing the data once it is un-blinded later this summer."

About the Isolagen Process(TM) and Isolagen Therapy(TM)

The Isolagen Process(TM) is an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient's own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient's skin. This treatment, known as the Isolagen Therapy, is designed to improve skin damage caused by the normal effects of aging, sun damage, acne and burns.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
2. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... WASHINGTON, Nov. 1 Multiple myeloma is one,of the ... U.S., but,survival rates have risen dramatically over the past ... to new types of drugs,and aggressive therapeutic interventions such ... studies prepublished online in Blood, the,official journal of the ...
... IRVINE, Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: ... data,from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). ... funded cooperative,group study conducted by the Children,s Oncology Group ... of patients originally treated in the Phase,3 trial. The ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
(Date:7/31/2014)... The study, The Truth Behind Variation in ... care payments for four clinical areas—congestive heart failure, acute ... and knees). Using the definition of episodes of ... program, the study examines these clinical areas within the ... , “Our study reaffirms that, in most instances, the ...
(Date:7/30/2014)... Riverdale, NJ (PRWEB) July 31, 2014 ... in Macy’s ninth annual national “Shop For A Cause” ... For A Cause” is a unique one-day-only shopping event ... helped raise more than $44 million for charities across ... year’s event by purchasing shopping passes from Push to ...
(Date:7/30/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... welcome Douglas A. Fecher President and CEO, Wright-Patt Credit ... , Fecher, is a foremost financial CEO with an ... vice president of lending and later chief operating officer ... 2000, Fecher has led the Beavercreek-based Wright-Patt Credit Union ...
(Date:7/30/2014)... 31, 2014 WalkingSticksandCane.com has just ... The ladies will love the new European fashions and the ... These sticks and canes are from one from one of ... of the styles re unique and offer the consumer the ... Blackthorn Walking Sticks are some of the rarest and most ...
(Date:7/30/2014)... born with severe combined immunodeficiency (SCID) can be successfully ... to experts led by Memorial Sloan Kettering,s Richard J. ... transplant protocols. Their review will be published in the ... of Medicine . , SCID is a group of ... malfunction. When this breakdown occurs, babies no longer have ...
Breaking Medicine News(10 mins):Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2
... Despite of the significant improvements in dialysis treatments, over ... U.S. Hemodialysis International, which published the// study, finds ... malnutrition. ,Large Body Mass Combats Effects ... what has been termed the “obesity paradox,” wherein obesity ...
... health crisis triggered by the death of over 40 ... institution's laboratory, has prompted Panamanian President// Martin Torrijos to ... ,Torrijos said that the government had since closed ... Body (CSS), permanently in a bid to win back ...
... a new study, septic shock—a dangerous, often deadly runaway ... research also suggests how a drug might// temper sepsis. ... been revealed in an experimental animal. ... Sabin Professor of Microbiology and Molecular Pathogenesis at NYU ...
... grow old in good health should have strong grip, not ... recent study.// ,A 40-year study of nearly 6000 ... nine factors that were good predictors of which middle-aged men ... ,The nine factors were: not being overweight, low blood sugar ...
... women who complain of severe itching and redness of skin ... intercourse that has been now confirmed by doctors as a ... present in semen. Thankfully doctors have given the hope to ... according to the report made in LiveScience. ,The ...
... More than 80,000 people in the United States are on ... for the death of a matching donor, but more and ... ,Last year nearly 7,000 people donated a kidney, segment of ... in need of a transplant. In fact at some major ...
Cached Medicine News:Health News:New Study Finds On/Off Switch for Septic Shock 2Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: